A recent blog post published on Health Affairs highlights some key reasons why indirect benefits should be factored into value assessments.
The authors, National Pharmaceutical Council Vice President of Research Michael Ciarametaro et al., suggest indirect benefits in value assessments have “the potential to dramatically change their determinations of treatment value.”
“Second, if value assessment frameworks do not account for improvements in indirect benefits, the true value of new treatments and innovations entering the market cannot be understood, realized, or rewarded,” they write. “Underestimation of treatment value can unduly impair access to needed medications for patients and create undesirable market incentives for continued biomedical innovation.”
To read the full blog post, click here.